Relativity Appoints Steve Couling as Chief Sales Officer
Couling's expertise to steer growth, customer commitment amid new age of AI and data evolution
"Steve has long been a driving force in Relativity's rapid expansion and evolution as a global market leader," said
Couling joined Relativity in 2012 as the first employee hired outside of
Couling began his career at Relativity as Director of International Sales before becoming the Vice President of International Sales in 2016 and Managing Director and Vice President Sales EMEA in 2019. In 2023 he moved from
"It's been enlightening to be on both the service provider and vendor sides with a front row seat to watching the industry advance amidst an evolution of cloud technology and constant innovation," said Couling. "I look forward to applying my industry experience to continue to champion Relativity's customers' and partners' needs and support the sales team through this next phase of growth."
Couling succeeds
"I'm grateful for
About Relativity
Relativity makes software to help users organize data, discover the truth and act on it. Its SaaS product, RelativityOne, manages large volumes of data and quickly identifies key issues during litigation and internal investigations. Relativity has more than 300,000 users in approximately 40 countries serving thousands of organizations globally primarily in legal, financial services and government sectors, including the U.S. Department of Justice and 198 of the Am Law 200. Please contact Relativity at [email protected] or visit www.relativity.com for more information.
CONTACT: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/relativity-appoints-steve-couling-as-chief-sales-officer-302031362.html
SOURCE Relativity
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PhilWeb Elects Conglomerate Leader Lance Y. Gokongwei as Chairman to Accelerate AI Infrastructure and Transnational Ecosystem Expansion
- AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies
- Yuchen Liu Examines Data-Driven Financial Risk Management for Multinational Enterprises
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share